Charles River Laboratories International Beats Analyst Estimates on EPS
Charles River Laboratories International (NYS: CRL) reported earnings on July 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 29 (Q2), Charles River Laboratories International met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded slightly. Non-GAAP earnings per share dropped slightly. GAAP earnings per share dropped.
Margins shrank across the board.
Charles River Laboratories International chalked up revenue of $292.9 million. The 11 analysts polled by S&P Capital IQ looked for net sales of $293.8 million on the same basis. GAAP reported sales were 2.9% higher than the prior-year quarter's $284.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
EPS came in at $0.73. The 15 earnings estimates compiled by S&P Capital IQ predicted $0.71 per share. Non-GAAP EPS of $0.73 for Q2 were 2.7% lower than the prior-year quarter's $0.75 per share. GAAP EPS of $0.56 for Q2 were 11% lower than the prior-year quarter's $0.63 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the quarter, gross margin was 35.0%, 140 basis points worse than the prior-year quarter. Operating margin was 14.7%, 260 basis points worse than the prior-year quarter. Net margin was 9.3%, 140 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $291.0 million. On the bottom line, the average EPS estimate is $0.71.
Next year's average estimate for revenue is $1.17 billion. The average EPS estimate is $2.82.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $45.50.
Looking for alternatives to Charles River Laboratories International? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Charles River Laboratories International to My Watchlist.
The article Charles River Laboratories International Beats Analyst Estimates on EPS originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month. TMFDisclosureHere
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.